AstraZeneca-Alexion US clearance shows large pharma deals can still avoid deep probes

Summary

The clearance of AstraZeneca's proposed acquisition of Alexion by the US Federal Trade Commission shows that large pharmaceutical deals can still escape lengthy scrutiny during the Biden administration despite promises for more aggressive enforcement.